首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1970768

動物幹細胞療法市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Animal Stem Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球動物幹細胞治療市場預計將從 2025 年的 2.4011 億美元成長到 2031 年的 3.4389 億美元，複合年成長率為 6.17%。

該領域專注於再生醫學，利用自體或異體幹細胞促進組織修復，特別適用於伴侶動物和馬匹的骨關節炎和軟組織損傷。推動該行業發展的主要因素是寵物人性化趨勢的文化轉變以及老齡化相關整形外科疾病發病率的上升。這些因素凸顯了開發有效、非侵入性治療方法以取代傳統藥物療法的必要性。因此，人們對旨在顯著改善老年動物生活品質的先進醫療干預措施的需求日益成長。

市場概覽
預測期	2027-2031
市場規模：2025年	2.4011億美元
市場規模：2031年	3.4389億美元
複合年成長率：2026-2031年	6.17%
成長最快的細分市場	動物醫院
最大的市場	北美洲

儘管成長潛力巨大，但該市場仍面臨許多障礙，因為這些療法的高昂費用限制了許多寵物飼主的接受度。除了經濟限制外，不同司法管轄區缺乏統一的法規結構也是其廣泛應用的主要障礙。根據美國寵物用品協會（APPA）的數據，2024年美國獸醫醫療和產品總銷售額將達398億美元。雖然如此巨大的支出表明先進獸醫解決方案擁有穩固的經濟基礎，但再生醫學的高昂價格仍然是其普及應用的一大障礙。

市場促進因素

慢性病和整形外科疾病的日益普遍是全球動物幹細胞治療市場的主要驅動力。隨著伴侶動物壽命的延長，骨關節炎和軟組織損傷等與老齡化相關的疾病發生率也在上升，因此迫切需要能夠提供長期症狀緩解而非僅僅緩解症狀的再生療法。 2025年6月《獸醫時報》發表的一項關於早期骨關節炎診斷的臨床評估顯示，高達23.6%的幼犬出現該疾病的徵兆，凸顯了早期干預的緊迫性。慢性病發病率的上升趨勢促使獸醫將幹細胞療法作為緩解疾病方法納入標準治療方案中。

同時，伴侶動物日益普及以及寵物人性化趨勢的增強，正顯著加速市場成長。飼主越來越將寵物視為家庭成員，也更願意投資先進的醫療手段來維護它們的健康。根據澳洲動物醫學會2025年9月發布的報告，寵物擁有率預計將大幅成長，目前已有73%的家庭擁有寵物。這種情感紐帶得益於經濟保障的增強。北美寵物健康保險協會在2025年4月發布的報告顯示，截至2024年底，美國寵物保險總保費將達到47億美元，這使得擴大再生醫學的覆蓋範圍在經濟上成為可能。

市場挑戰

再生醫學手術費用飆升是全球動物幹細胞治療市場擴張的主要障礙。這些治療方法涉及複雜的採集、處理和再植入通訊協定，需要專用設備和訓練有素的獸醫專業人員，因此成本極高。因此，目標客戶群主要限於高所得寵物飼主，使得大多數市場參與者幾乎無法獲得這些先進的治療。這種經濟上的排他性阻礙了幹細胞療法成為多種整形外科疾病的標準療法，使其仍然是小眾的加值服務，而不是大眾市場的解決方案。

近期獸醫支出模式的變化進一步印證了這個經濟障礙，顯示消費者預算日益緊張。根據美國獸醫協會（AVMA）統計，2024年美國寵物飼主在獸醫方面的總支出較前一年下降了4%。支出下降凸顯了消費者對醫療保健成本上漲的敏感性，並表明面臨經濟壓力的飼主更有可能避免昂貴的非必要手術。由於幹細胞療法價格昂貴，這種普遍的支出減少趨勢將直接阻礙市場擴張所需的普及率。

市場趨勢

目前，市場正經歷一場根本性的轉變，從勞動密集的自體移植轉向可擴展、即時取得的異體「現成」幹細胞療法。這一趨勢將消除諸多物流障礙，使診所能夠儲備通用供體細胞，從而縮短個別組織採集前置作業時間並降低治療成本。目前，大量資金正被投入到推動大規模生產治療方法的轉型中。例如，DVM360在2025年7月報道稱，Gallant Therapeutics已獲得1,800萬美元的B輪資金籌措，用於加速其即用型間質幹細胞產品的商業化。

同時，將再生醫學融入常規獸醫診療通訊協定的趨勢日益明顯。這些治療方法正從專科醫院走向常規臨床服務。集中處理和儲存服務的日益普及，使得全科獸醫能夠擴大將再生醫學應用於慢性疾病（例如骨關節炎）的治療，而無需專門的醫療機構。這種主流化趨勢體現在整個產業內不斷上升的採用率。根據VetStem公司2025年4月發布的新聞稿，該公司已成功處理超過4萬例幹細胞療法，這表明這些治療方法正在標準獸醫護理中發揮重要作用。

The Global Animal Stem Cell Therapy Market is projected to expand from USD 240.11 Million in 2025 to USD 343.89 Million by 2031, reflecting a compound annual growth rate of 6.17%. This sector focuses on regenerative medical treatments that employ autologous or allogeneic stem cells to facilitate tissue repair, specifically targeting osteoarthritis and soft tissue injuries in companion animals and horses. The industry is primarily bolstered by the cultural shift toward pet humanization and the increasing incidence of age-related orthopedic ailments, which necessitate effective, non-invasive alternatives to conventional pharmaceutical management. Consequently, these drivers are fostering a rising demand for advanced healthcare interventions aimed at significantly improving the quality of life for aging animals.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 240.11 Million
Market Size 2031	USD 343.89 Million
CAGR 2026-2031	6.17%
Fastest Growing Segment	Veterinary Hospitals
Largest Market	North America

Despite this growth potential, the market faces substantial obstacles due to the prohibitive costs associated with these procedures, which limit accessibility for many pet owners. Financial constraints, coupled with inconsistent regulatory frameworks across different jurisdictions, create significant barriers to mass adoption. Data from the American Pet Products Association indicates that veterinary care and product sales in the United States totaled $39.8 billion in 2024. While this substantial expenditure demonstrates a solid economic foundation for advanced veterinary solutions, the elevated price point of regenerative therapies remains a critical hurdle preventing widespread implementation.

Market Driver

The escalating prevalence of chronic and orthopedic veterinary diseases serves as the primary catalyst driving the global animal stem cell therapy market. As the lifespan of companion animals increases, so does the occurrence of age-related conditions such as osteoarthritis and soft tissue injuries, creating a critical need for regenerative treatments that provide long-term relief beyond simple palliative care. Clinical assessments referenced in a June 2025 Vet Times article on early osteoarthritis diagnosis reveal that up to 23.6% of young dogs now exhibit signs of the disease, underscoring the urgent demand for early-stage interventions. This growing burden of chronic illness compels veterinarians to integrate stem cell therapies as a standard, disease-modifying approach to care.

Concurrently, market growth is significantly amplified by the increasing adoption of companion animals and the trend of pet humanization. Owners increasingly view their pets as integral family members, demonstrating a higher propensity to invest in advanced medical procedures to ensure their well-being. A September 2025 report by Animal Medicines Australia notes that pet ownership rates have surged, with 73% of households now owning a pet. This emotional commitment is supported by strengthening financial safeguards; the North American Pet Health Insurance Association reported in April 2025 that total U.S. pet insurance premiums reached $4.7 billion by the end of 2024, providing the economic means to facilitate wider access to these regenerative therapies.

Market Challenge

The prohibitive cost of regenerative procedures acts as a major barrier restricting the scalability of the global animal stem cell therapy market. These therapies involve complex extraction, processing, and re-implantation protocols that require specialized equipment and highly trained veterinary personnel, leading to substantial treatment fees. Consequently, the addressable customer base is narrowed significantly to high-income pet owners, effectively rendering these advanced treatments inaccessible for the majority of the market. This economic exclusivity prevents stem cell therapy from becoming a standard of care for widespread orthopedic conditions, relegating it to a niche premium service rather than a mass-market solution.

This financial friction is further evidenced by recent shifts in veterinary consumption patterns, which indicate a tightening of consumer budgets. According to the American Veterinary Medical Association, overall veterinary spending by pet owners in the United States decreased by 4% in 2024 compared to the previous year. This contraction in expenditure highlights the sensitivity of clients to rising healthcare costs, suggesting that when faced with economic pressures, owners are likely to forgo expensive elective procedures. As stem cell treatments represent a significant financial outlay, this broader trend of reduced spending power directly dampens the adoption rates necessary for robust market expansion.

Market Trends

The market is undergoing a fundamental transition toward allogeneic "off-the-shelf" stem cell therapies, moving away from labor-intensive autologous procedures to scalable, immediately available solutions. This trend addresses critical logistical barriers by enabling clinics to stock universal donor cells, thereby reducing the lead times and procedural costs associated with individual tissue harvesting. Significant capital is currently supporting this pivot toward mass-producible therapeutics; for instance, DVM360 reported in July 2025 that Gallant Therapeutics secured $18 million in Series B financing specifically to accelerate the commercialization of its off-the-shelf uterine-derived mesenchymal stem cell products.

Simultaneously, the integration of regenerative medicine into general veterinary practice protocols is expanding, as these therapies graduate from niche specialty hospitals to routine clinical offerings. Enhanced access to centralized processing and banking services has allowed general practitioners to increasingly incorporate regenerative treatments for chronic conditions like osteoarthritis without requiring specialized onsite laboratory infrastructure. This mainstream adoption is quantified by rising usage rates across the sector; according to a broad press release by VetStem, Inc. in April 2025, the company has successfully processed over 40,000 stem cell treatments, demonstrating the established role of these interventions in standard veterinary care.

Key Market Players

Ardent Animal Health LLC
Vet Stem Inc
Medrego Limited Liability Company (SIA)
Veterinary Regenerative Medicine
Celavie Biosciences LLC
Magellan Stem Cells Pty Ltd
Animal Cell Therapies, Inc.
Cell Therapy Sciences Ltd

Report Scope

In this report, the Global Animal Stem Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Stem Cell Therapy Market, By Type

Dogs Stem Cell Therapy
Horses Stem Cell Therapy

Animal Stem Cell Therapy Market, By Application

Veterinary Hospitals
Research Organizations

Animal Stem Cell Therapy Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Stem Cell Therapy Market.

Available Customizations:

Global Animal Stem Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Stem Cell Therapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Dogs Stem Cell Therapy, Horses Stem Cell Therapy)
- 5.2.2. By Application (Veterinary Hospitals, Research Organizations)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Animal Stem Cell Therapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Animal Stem Cell Therapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Animal Stem Cell Therapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Animal Stem Cell Therapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Animal Stem Cell Therapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Animal Stem Cell Therapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. France Animal Stem Cell Therapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Animal Stem Cell Therapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Animal Stem Cell Therapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Animal Stem Cell Therapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia Pacific Animal Stem Cell Therapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Animal Stem Cell Therapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Animal Stem Cell Therapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Animal Stem Cell Therapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Animal Stem Cell Therapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Animal Stem Cell Therapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. Middle East & Africa Animal Stem Cell Therapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Animal Stem Cell Therapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Animal Stem Cell Therapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Animal Stem Cell Therapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. South America Animal Stem Cell Therapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Animal Stem Cell Therapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Animal Stem Cell Therapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Animal Stem Cell Therapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Animal Stem Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Ardent Animal Health LLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Vet Stem Inc
15.3. Medrego Limited Liability Company (SIA)
15.4. Veterinary Regenerative Medicine
15.5. Celavie Biosciences LLC
15.6. Magellan Stem Cells Pty Ltd
15.7. Animal Cell Therapies, Inc.
15.8. Cell Therapy Sciences Ltd